Drugs / BI 765179
last change Apr 2026 re-read 2 minutes ago

BI 765179

Developed for
neoplasm
Investigated by
Boehringer Ingelheim

Trials 1 · a red edge is where a trial was stopped

20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04958239 Oct 2021 → Apr 2026 overdue neoplasm Boehringer Ingelheim Active not recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as BI 765179 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04958239